XML 220 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation (Tables)
 3 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Awards Outstanding
The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:
As of December 31, 2024
2013 Plan2021 PlanInducement AwardsTotal
Granted and outstanding awards:
Options1,248,038 32,151 602,939 1,883,128 
Restricted stock units1,607,885 2,943,382 512,507 5,063,774 
Total2,855,923 2,975,533 1,115,446 6,946,902 
Schedule of Share-Based Payment Arrangement, Expensed
The following table summarizes stock-based compensation expenses included in operating expenses:
Three Months Ended December 31,
20242023
(in thousands)
Research and development$6,846 $7,823 
General and administrative7,329 9,862 
Total$14,175 $17,685 
Schedule of Summarized Information about Stock Options
The following table presents a summary of the stock option activity for the three months ended December 31, 2024:
SharesWeighted-
Average
Exercise
Price
Per Share		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
Outstanding at September 30, 2024
1,978,516$23.39 
Granted—— 
Cancelled or expired(25,882)40.20 
Exercised(69,506)9.06 
Outstanding at December 31, 2024
1,883,128$23.69 3.3$12,408,737 
Exercisable at December 31, 2024
1,882,710$23.68 3.3$12,408,737 
Schedule of Share Activity Related to RSUs
The following table summarizes the activity of the Company’s RSUs:
Number of
RSUs		Weighted-
Average
Grant
Date
Fair Value
Per Share
Outstanding at September 30, 2024
4,913,312$49.61 
Granted493,14820.20 
Vested(209,122)62.88 
Forfeited(133,564)35.12 
Outstanding at December 31, 2024
5,063,774$46.58